Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054-Reference-Cited by-同舟云学术

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Published:2018-04-30 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Li Yiwen,Carpenito Carmine,Wang George,Surguladze David,Forest Amelie,Malabunga Maria,Murphy Mary,Zhang Yiwei,Sonyi Andreas,Chin Darin,Burtrum Douglas,Inigo Ivan,Pennello Anthony,Shen Leyi,Malherbe Laurent,Chen Xinlei,Hall Gerald,Haidar Jaafar N.,Ludwig Dale L.,Novosiadly Ruslan D.,Kalos Michael

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0329-7.pdf

Reference30 articles.

1. Baxter AG, Hodgkin PD. Activation rules: the two-signal theories of immune activation. Nat Rev Immunol. 2002;2(6):439–46.

2. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.

3. Yearley JH, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–67.

4. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42.

5. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195–201.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2;Frontiers in Immunology;2023-10-24

2. Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy;Viruses;2023-09-09

3. CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways;Immuno;2023-07-07

4. Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment;Pharmaceutics;2023-05-26

5. Humanized mouse models for immuno-oncology research;Nature Reviews Clinical Oncology;2023-01-12